Global Methotrexate Market

Methotrexate Comprehensive Study by Type (Tablet, Injection), Application (Cancer, Arthritis, Auto-Immune Diseases, Others), Sales Channel (Pharmacy Stores, Online Pharmacies), Dosage (5 mg, 7.5 mg, 10 mg, 15 mg, Others), End User (Hospitals, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2030

Methotrexate Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.25%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Methotrexate Market Scope
Methotrexate is a prescription medication. Approved by the United States FDA (Food and Drug Administration), Methotrexate belongs to a class of drugs called antimetabolites, or folic acid antagonists. It works by slowing or stopping the growth of cancer cells and suppressing the immune system. Methotrexate is used to treat certain types of cancer of the breast, skin, head, and neck, or lung. Methotrexate is one of the most effective and widely used medications for treating inflammatory types of arthritis psoriasis. It’s also one of the safest arthritis drugs, despite a common misconception among many patients that methotrexate is highly toxic

According to AMA, the Global Methotrexate market is expected to see growth rate of 5.25%

The market for Methotrexate is highly fragmented with the presence of many manufacturers worldwide. The companies for Methotrexate may be involved in implementing strategies like mergers, acquisitions, collaborations, and new improved product launches to increase their market share. An increase in the market of Methotrexate can be predicted due to the rise in medicals conditions like cancer worldwide. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Methotrexate market throughout the predicted period.

Pfizer Inc. (United States), GlaxoSmithKline (United Kingdom), Cumberland Pharmaceuticals Inc. (United States), Cadila Healthcare (India), Cipla Limited (India), Rosemont Pharmaceuticals Limited (United Kingdom), Antares Pharma Inc. (United States), Medac Pharma Inc. (United States), Accord Healthcare Limited (United States) and Sun Pharma Laboratories Ltd (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Alkem Laboratories Ltd. (India), Ranbaxy Laboratories Ltd. (India), Ipca Laboratories Private Ltd. (India), Mylan (United States), Sandoz (Novartis), Germany, Hikma Pharmaceuticals (United Kingdom), Teva Pharmaceutical Industries (Israel), ROVI Pharmaceutical Company, Pharmacia (United States), Remedica Ltd (Cyprus) and Kalbe Farma (Indonesia).

Segmentation Overview
The study have segmented the market of Global Methotrexate market by Type (Tablet and Injection), by Application (Cancer, Arthritis, Auto-Immune Diseases and Others) and Region with country level break-up.

On the basis of geography, the market of Methotrexate has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
New generation Methotrexate medications that intend to minimize the after-effects of long term medication consumption

Market Growth Drivers:
The surge in cancer patients worldwide needing affordable cancer treatment medications has increased the demand for methotrexate and The presence of a large pediatric population globally suffering from chronic ailments has contributed to the widespread usage of methotrexate

Challenges:
The presence of Methotrexate intolerant patients has limited the usage of methotrexate and Tackling the possible long term side effects of methotrexate like kidney and liver damages

Restraints:
Usage of drugs like cyclosporine and leflunomide used as an alternative to methotrexate for the management of various forms of cancer

Opportunities:
Due to affordability, Methotrexate offers a boost to the cancer treatment pharmaceutical segment

Market Leaders and their Expansionary Development Strategies
In July 2020, LGM pharma acquired Nexgen Pharma Inc. formulation and drug manufacturing business this Acquistion enabled LGM pharma to offer complete set
In December 2019, Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, received approval from the United States Food and Drug Administration (FDA) for RediTrex™, its new line of methotrexate products


Key Target Audience
Pharmaceutical Companies, Pharmacy Chains/Drug Stores, Drug Suppliers/Traders, Drug Exporters/Importers, Investors, Regulatory and Government Bodies, Upstream Vendors, Downstream Vendors and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Type
  • Tablet
  • Injection
By Application
  • Cancer
  • Arthritis
  • Auto-Immune Diseases
  • Others
By Sales Channel
  • Pharmacy Stores
  • Online Pharmacies

By Dosage
  • 5 mg
  • 7.5 mg
  • 10 mg
  • 15 mg
  • Others

By End User
  • Hospitals
  • Specialty Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The surge in cancer patients worldwide needing affordable cancer treatment medications has increased the demand for methotrexate
      • 3.2.2. The presence of a large pediatric population globally suffering from chronic ailments has contributed to the widespread usage of methotrexate
    • 3.3. Market Challenges
      • 3.3.1. The presence of Methotrexate intolerant patients has limited the usage of methotrexate
      • 3.3.2. Tackling the possible long term side effects of methotrexate like kidney and liver damages
    • 3.4. Market Trends
      • 3.4.1. New generation Methotrexate medications that intend to minimize the after-effects of long term medication consumption
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Methotrexate, by Type, Application, Sales Channel, Dosage, End User and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Methotrexate (Value)
      • 5.2.1. Global Methotrexate by: Type (Value)
        • 5.2.1.1. Tablet
        • 5.2.1.2. Injection
      • 5.2.2. Global Methotrexate by: Application (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Arthritis
        • 5.2.2.3. Auto-Immune Diseases
        • 5.2.2.4. Others
      • 5.2.3. Global Methotrexate by: Sales Channel (Value)
        • 5.2.3.1. Pharmacy Stores
        • 5.2.3.2. Online Pharmacies
      • 5.2.4. Global Methotrexate by: Dosage (Value)
        • 5.2.4.1. 5 mg
        • 5.2.4.2. 7.5 mg
        • 5.2.4.3. 10 mg
        • 5.2.4.4. 15 mg
        • 5.2.4.5. Others
      • 5.2.5. Global Methotrexate by: End User (Value)
        • 5.2.5.1. Hospitals
        • 5.2.5.2. Specialty Clinics
        • 5.2.5.3. Others
      • 5.2.6. Global Methotrexate Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Methotrexate (Volume)
      • 5.3.1. Global Methotrexate by: Type (Volume)
        • 5.3.1.1. Tablet
        • 5.3.1.2. Injection
      • 5.3.2. Global Methotrexate by: Application (Volume)
        • 5.3.2.1. Cancer
        • 5.3.2.2. Arthritis
        • 5.3.2.3. Auto-Immune Diseases
        • 5.3.2.4. Others
      • 5.3.3. Global Methotrexate by: Sales Channel (Volume)
        • 5.3.3.1. Pharmacy Stores
        • 5.3.3.2. Online Pharmacies
      • 5.3.4. Global Methotrexate by: Dosage (Volume)
        • 5.3.4.1. 5 mg
        • 5.3.4.2. 7.5 mg
        • 5.3.4.3. 10 mg
        • 5.3.4.4. 15 mg
        • 5.3.4.5. Others
      • 5.3.5. Global Methotrexate by: End User (Volume)
        • 5.3.5.1. Hospitals
        • 5.3.5.2. Specialty Clinics
        • 5.3.5.3. Others
      • 5.3.6. Global Methotrexate Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Methotrexate (Price)
      • 5.4.1. Global Methotrexate by: Type (Price)
  • 6. Methotrexate: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cumberland Pharmaceuticals Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cadila Healthcare (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cipla Limited (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Rosemont Pharmaceuticals Limited (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Antares Pharma Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Medac Pharma Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Accord Healthcare Limited (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sun Pharma Laboratories Ltd (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Methotrexate Sale, by Type, Application, Sales Channel, Dosage, End User and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Methotrexate (Value)
      • 7.2.1. Global Methotrexate by: Type (Value)
        • 7.2.1.1. Tablet
        • 7.2.1.2. Injection
      • 7.2.2. Global Methotrexate by: Application (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Arthritis
        • 7.2.2.3. Auto-Immune Diseases
        • 7.2.2.4. Others
      • 7.2.3. Global Methotrexate by: Sales Channel (Value)
        • 7.2.3.1. Pharmacy Stores
        • 7.2.3.2. Online Pharmacies
      • 7.2.4. Global Methotrexate by: Dosage (Value)
        • 7.2.4.1. 5 mg
        • 7.2.4.2. 7.5 mg
        • 7.2.4.3. 10 mg
        • 7.2.4.4. 15 mg
        • 7.2.4.5. Others
      • 7.2.5. Global Methotrexate by: End User (Value)
        • 7.2.5.1. Hospitals
        • 7.2.5.2. Specialty Clinics
        • 7.2.5.3. Others
      • 7.2.6. Global Methotrexate Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Methotrexate (Volume)
      • 7.3.1. Global Methotrexate by: Type (Volume)
        • 7.3.1.1. Tablet
        • 7.3.1.2. Injection
      • 7.3.2. Global Methotrexate by: Application (Volume)
        • 7.3.2.1. Cancer
        • 7.3.2.2. Arthritis
        • 7.3.2.3. Auto-Immune Diseases
        • 7.3.2.4. Others
      • 7.3.3. Global Methotrexate by: Sales Channel (Volume)
        • 7.3.3.1. Pharmacy Stores
        • 7.3.3.2. Online Pharmacies
      • 7.3.4. Global Methotrexate by: Dosage (Volume)
        • 7.3.4.1. 5 mg
        • 7.3.4.2. 7.5 mg
        • 7.3.4.3. 10 mg
        • 7.3.4.4. 15 mg
        • 7.3.4.5. Others
      • 7.3.5. Global Methotrexate by: End User (Volume)
        • 7.3.5.1. Hospitals
        • 7.3.5.2. Specialty Clinics
        • 7.3.5.3. Others
      • 7.3.6. Global Methotrexate Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Methotrexate (Price)
      • 7.4.1. Global Methotrexate by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Methotrexate: by Type(USD Million)
  • Table 2. Methotrexate Tablet , by Region USD Million (2018-2023)
  • Table 3. Methotrexate Injection , by Region USD Million (2018-2023)
  • Table 4. Methotrexate: by Application(USD Million)
  • Table 5. Methotrexate Cancer , by Region USD Million (2018-2023)
  • Table 6. Methotrexate Arthritis , by Region USD Million (2018-2023)
  • Table 7. Methotrexate Auto-Immune Diseases , by Region USD Million (2018-2023)
  • Table 8. Methotrexate Others , by Region USD Million (2018-2023)
  • Table 9. Methotrexate: by Sales Channel(USD Million)
  • Table 10. Methotrexate Pharmacy Stores , by Region USD Million (2018-2023)
  • Table 11. Methotrexate Online Pharmacies , by Region USD Million (2018-2023)
  • Table 12. Methotrexate: by Dosage(USD Million)
  • Table 13. Methotrexate 5 mg , by Region USD Million (2018-2023)
  • Table 14. Methotrexate 7.5 mg , by Region USD Million (2018-2023)
  • Table 15. Methotrexate 10 mg , by Region USD Million (2018-2023)
  • Table 16. Methotrexate 15 mg , by Region USD Million (2018-2023)
  • Table 17. Methotrexate Others , by Region USD Million (2018-2023)
  • Table 18. Methotrexate: by End User(USD Million)
  • Table 19. Methotrexate Hospitals , by Region USD Million (2018-2023)
  • Table 20. Methotrexate Specialty Clinics , by Region USD Million (2018-2023)
  • Table 21. Methotrexate Others , by Region USD Million (2018-2023)
  • Table 22. South America Methotrexate, by Country USD Million (2018-2023)
  • Table 23. South America Methotrexate, by Type USD Million (2018-2023)
  • Table 24. South America Methotrexate, by Application USD Million (2018-2023)
  • Table 25. South America Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 26. South America Methotrexate, by Dosage USD Million (2018-2023)
  • Table 27. South America Methotrexate, by End User USD Million (2018-2023)
  • Table 28. Brazil Methotrexate, by Type USD Million (2018-2023)
  • Table 29. Brazil Methotrexate, by Application USD Million (2018-2023)
  • Table 30. Brazil Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 31. Brazil Methotrexate, by Dosage USD Million (2018-2023)
  • Table 32. Brazil Methotrexate, by End User USD Million (2018-2023)
  • Table 33. Argentina Methotrexate, by Type USD Million (2018-2023)
  • Table 34. Argentina Methotrexate, by Application USD Million (2018-2023)
  • Table 35. Argentina Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 36. Argentina Methotrexate, by Dosage USD Million (2018-2023)
  • Table 37. Argentina Methotrexate, by End User USD Million (2018-2023)
  • Table 38. Rest of South America Methotrexate, by Type USD Million (2018-2023)
  • Table 39. Rest of South America Methotrexate, by Application USD Million (2018-2023)
  • Table 40. Rest of South America Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 41. Rest of South America Methotrexate, by Dosage USD Million (2018-2023)
  • Table 42. Rest of South America Methotrexate, by End User USD Million (2018-2023)
  • Table 43. Asia Pacific Methotrexate, by Country USD Million (2018-2023)
  • Table 44. Asia Pacific Methotrexate, by Type USD Million (2018-2023)
  • Table 45. Asia Pacific Methotrexate, by Application USD Million (2018-2023)
  • Table 46. Asia Pacific Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 47. Asia Pacific Methotrexate, by Dosage USD Million (2018-2023)
  • Table 48. Asia Pacific Methotrexate, by End User USD Million (2018-2023)
  • Table 49. China Methotrexate, by Type USD Million (2018-2023)
  • Table 50. China Methotrexate, by Application USD Million (2018-2023)
  • Table 51. China Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 52. China Methotrexate, by Dosage USD Million (2018-2023)
  • Table 53. China Methotrexate, by End User USD Million (2018-2023)
  • Table 54. Japan Methotrexate, by Type USD Million (2018-2023)
  • Table 55. Japan Methotrexate, by Application USD Million (2018-2023)
  • Table 56. Japan Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 57. Japan Methotrexate, by Dosage USD Million (2018-2023)
  • Table 58. Japan Methotrexate, by End User USD Million (2018-2023)
  • Table 59. India Methotrexate, by Type USD Million (2018-2023)
  • Table 60. India Methotrexate, by Application USD Million (2018-2023)
  • Table 61. India Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 62. India Methotrexate, by Dosage USD Million (2018-2023)
  • Table 63. India Methotrexate, by End User USD Million (2018-2023)
  • Table 64. South Korea Methotrexate, by Type USD Million (2018-2023)
  • Table 65. South Korea Methotrexate, by Application USD Million (2018-2023)
  • Table 66. South Korea Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 67. South Korea Methotrexate, by Dosage USD Million (2018-2023)
  • Table 68. South Korea Methotrexate, by End User USD Million (2018-2023)
  • Table 69. Taiwan Methotrexate, by Type USD Million (2018-2023)
  • Table 70. Taiwan Methotrexate, by Application USD Million (2018-2023)
  • Table 71. Taiwan Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 72. Taiwan Methotrexate, by Dosage USD Million (2018-2023)
  • Table 73. Taiwan Methotrexate, by End User USD Million (2018-2023)
  • Table 74. Australia Methotrexate, by Type USD Million (2018-2023)
  • Table 75. Australia Methotrexate, by Application USD Million (2018-2023)
  • Table 76. Australia Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 77. Australia Methotrexate, by Dosage USD Million (2018-2023)
  • Table 78. Australia Methotrexate, by End User USD Million (2018-2023)
  • Table 79. Rest of Asia-Pacific Methotrexate, by Type USD Million (2018-2023)
  • Table 80. Rest of Asia-Pacific Methotrexate, by Application USD Million (2018-2023)
  • Table 81. Rest of Asia-Pacific Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Methotrexate, by Dosage USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Methotrexate, by End User USD Million (2018-2023)
  • Table 84. Europe Methotrexate, by Country USD Million (2018-2023)
  • Table 85. Europe Methotrexate, by Type USD Million (2018-2023)
  • Table 86. Europe Methotrexate, by Application USD Million (2018-2023)
  • Table 87. Europe Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 88. Europe Methotrexate, by Dosage USD Million (2018-2023)
  • Table 89. Europe Methotrexate, by End User USD Million (2018-2023)
  • Table 90. Germany Methotrexate, by Type USD Million (2018-2023)
  • Table 91. Germany Methotrexate, by Application USD Million (2018-2023)
  • Table 92. Germany Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 93. Germany Methotrexate, by Dosage USD Million (2018-2023)
  • Table 94. Germany Methotrexate, by End User USD Million (2018-2023)
  • Table 95. France Methotrexate, by Type USD Million (2018-2023)
  • Table 96. France Methotrexate, by Application USD Million (2018-2023)
  • Table 97. France Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 98. France Methotrexate, by Dosage USD Million (2018-2023)
  • Table 99. France Methotrexate, by End User USD Million (2018-2023)
  • Table 100. Italy Methotrexate, by Type USD Million (2018-2023)
  • Table 101. Italy Methotrexate, by Application USD Million (2018-2023)
  • Table 102. Italy Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 103. Italy Methotrexate, by Dosage USD Million (2018-2023)
  • Table 104. Italy Methotrexate, by End User USD Million (2018-2023)
  • Table 105. United Kingdom Methotrexate, by Type USD Million (2018-2023)
  • Table 106. United Kingdom Methotrexate, by Application USD Million (2018-2023)
  • Table 107. United Kingdom Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 108. United Kingdom Methotrexate, by Dosage USD Million (2018-2023)
  • Table 109. United Kingdom Methotrexate, by End User USD Million (2018-2023)
  • Table 110. Netherlands Methotrexate, by Type USD Million (2018-2023)
  • Table 111. Netherlands Methotrexate, by Application USD Million (2018-2023)
  • Table 112. Netherlands Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 113. Netherlands Methotrexate, by Dosage USD Million (2018-2023)
  • Table 114. Netherlands Methotrexate, by End User USD Million (2018-2023)
  • Table 115. Rest of Europe Methotrexate, by Type USD Million (2018-2023)
  • Table 116. Rest of Europe Methotrexate, by Application USD Million (2018-2023)
  • Table 117. Rest of Europe Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 118. Rest of Europe Methotrexate, by Dosage USD Million (2018-2023)
  • Table 119. Rest of Europe Methotrexate, by End User USD Million (2018-2023)
  • Table 120. MEA Methotrexate, by Country USD Million (2018-2023)
  • Table 121. MEA Methotrexate, by Type USD Million (2018-2023)
  • Table 122. MEA Methotrexate, by Application USD Million (2018-2023)
  • Table 123. MEA Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 124. MEA Methotrexate, by Dosage USD Million (2018-2023)
  • Table 125. MEA Methotrexate, by End User USD Million (2018-2023)
  • Table 126. Middle East Methotrexate, by Type USD Million (2018-2023)
  • Table 127. Middle East Methotrexate, by Application USD Million (2018-2023)
  • Table 128. Middle East Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 129. Middle East Methotrexate, by Dosage USD Million (2018-2023)
  • Table 130. Middle East Methotrexate, by End User USD Million (2018-2023)
  • Table 131. Africa Methotrexate, by Type USD Million (2018-2023)
  • Table 132. Africa Methotrexate, by Application USD Million (2018-2023)
  • Table 133. Africa Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 134. Africa Methotrexate, by Dosage USD Million (2018-2023)
  • Table 135. Africa Methotrexate, by End User USD Million (2018-2023)
  • Table 136. North America Methotrexate, by Country USD Million (2018-2023)
  • Table 137. North America Methotrexate, by Type USD Million (2018-2023)
  • Table 138. North America Methotrexate, by Application USD Million (2018-2023)
  • Table 139. North America Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 140. North America Methotrexate, by Dosage USD Million (2018-2023)
  • Table 141. North America Methotrexate, by End User USD Million (2018-2023)
  • Table 142. United States Methotrexate, by Type USD Million (2018-2023)
  • Table 143. United States Methotrexate, by Application USD Million (2018-2023)
  • Table 144. United States Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 145. United States Methotrexate, by Dosage USD Million (2018-2023)
  • Table 146. United States Methotrexate, by End User USD Million (2018-2023)
  • Table 147. Canada Methotrexate, by Type USD Million (2018-2023)
  • Table 148. Canada Methotrexate, by Application USD Million (2018-2023)
  • Table 149. Canada Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 150. Canada Methotrexate, by Dosage USD Million (2018-2023)
  • Table 151. Canada Methotrexate, by End User USD Million (2018-2023)
  • Table 152. Mexico Methotrexate, by Type USD Million (2018-2023)
  • Table 153. Mexico Methotrexate, by Application USD Million (2018-2023)
  • Table 154. Mexico Methotrexate, by Sales Channel USD Million (2018-2023)
  • Table 155. Mexico Methotrexate, by Dosage USD Million (2018-2023)
  • Table 156. Mexico Methotrexate, by End User USD Million (2018-2023)
  • Table 157. Methotrexate Sales: by Type(K Units)
  • Table 158. Methotrexate Sales Tablet , by Region K Units (2018-2023)
  • Table 159. Methotrexate Sales Injection , by Region K Units (2018-2023)
  • Table 160. Methotrexate Sales: by Application(K Units)
  • Table 161. Methotrexate Sales Cancer , by Region K Units (2018-2023)
  • Table 162. Methotrexate Sales Arthritis , by Region K Units (2018-2023)
  • Table 163. Methotrexate Sales Auto-Immune Diseases , by Region K Units (2018-2023)
  • Table 164. Methotrexate Sales Others , by Region K Units (2018-2023)
  • Table 165. Methotrexate Sales: by Sales Channel(K Units)
  • Table 166. Methotrexate Sales Pharmacy Stores , by Region K Units (2018-2023)
  • Table 167. Methotrexate Sales Online Pharmacies , by Region K Units (2018-2023)
  • Table 168. Methotrexate Sales: by Dosage(K Units)
  • Table 169. Methotrexate Sales 5 mg , by Region K Units (2018-2023)
  • Table 170. Methotrexate Sales 7.5 mg , by Region K Units (2018-2023)
  • Table 171. Methotrexate Sales 10 mg , by Region K Units (2018-2023)
  • Table 172. Methotrexate Sales 15 mg , by Region K Units (2018-2023)
  • Table 173. Methotrexate Sales Others , by Region K Units (2018-2023)
  • Table 174. Methotrexate Sales: by End User(K Units)
  • Table 175. Methotrexate Sales Hospitals , by Region K Units (2018-2023)
  • Table 176. Methotrexate Sales Specialty Clinics , by Region K Units (2018-2023)
  • Table 177. Methotrexate Sales Others , by Region K Units (2018-2023)
  • Table 178. South America Methotrexate Sales, by Country K Units (2018-2023)
  • Table 179. South America Methotrexate Sales, by Type K Units (2018-2023)
  • Table 180. South America Methotrexate Sales, by Application K Units (2018-2023)
  • Table 181. South America Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 182. South America Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 183. South America Methotrexate Sales, by End User K Units (2018-2023)
  • Table 184. Brazil Methotrexate Sales, by Type K Units (2018-2023)
  • Table 185. Brazil Methotrexate Sales, by Application K Units (2018-2023)
  • Table 186. Brazil Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 187. Brazil Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 188. Brazil Methotrexate Sales, by End User K Units (2018-2023)
  • Table 189. Argentina Methotrexate Sales, by Type K Units (2018-2023)
  • Table 190. Argentina Methotrexate Sales, by Application K Units (2018-2023)
  • Table 191. Argentina Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 192. Argentina Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 193. Argentina Methotrexate Sales, by End User K Units (2018-2023)
  • Table 194. Rest of South America Methotrexate Sales, by Type K Units (2018-2023)
  • Table 195. Rest of South America Methotrexate Sales, by Application K Units (2018-2023)
  • Table 196. Rest of South America Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 197. Rest of South America Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 198. Rest of South America Methotrexate Sales, by End User K Units (2018-2023)
  • Table 199. Asia Pacific Methotrexate Sales, by Country K Units (2018-2023)
  • Table 200. Asia Pacific Methotrexate Sales, by Type K Units (2018-2023)
  • Table 201. Asia Pacific Methotrexate Sales, by Application K Units (2018-2023)
  • Table 202. Asia Pacific Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 203. Asia Pacific Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 204. Asia Pacific Methotrexate Sales, by End User K Units (2018-2023)
  • Table 205. China Methotrexate Sales, by Type K Units (2018-2023)
  • Table 206. China Methotrexate Sales, by Application K Units (2018-2023)
  • Table 207. China Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 208. China Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 209. China Methotrexate Sales, by End User K Units (2018-2023)
  • Table 210. Japan Methotrexate Sales, by Type K Units (2018-2023)
  • Table 211. Japan Methotrexate Sales, by Application K Units (2018-2023)
  • Table 212. Japan Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 213. Japan Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 214. Japan Methotrexate Sales, by End User K Units (2018-2023)
  • Table 215. India Methotrexate Sales, by Type K Units (2018-2023)
  • Table 216. India Methotrexate Sales, by Application K Units (2018-2023)
  • Table 217. India Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 218. India Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 219. India Methotrexate Sales, by End User K Units (2018-2023)
  • Table 220. South Korea Methotrexate Sales, by Type K Units (2018-2023)
  • Table 221. South Korea Methotrexate Sales, by Application K Units (2018-2023)
  • Table 222. South Korea Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 223. South Korea Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 224. South Korea Methotrexate Sales, by End User K Units (2018-2023)
  • Table 225. Taiwan Methotrexate Sales, by Type K Units (2018-2023)
  • Table 226. Taiwan Methotrexate Sales, by Application K Units (2018-2023)
  • Table 227. Taiwan Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 228. Taiwan Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 229. Taiwan Methotrexate Sales, by End User K Units (2018-2023)
  • Table 230. Australia Methotrexate Sales, by Type K Units (2018-2023)
  • Table 231. Australia Methotrexate Sales, by Application K Units (2018-2023)
  • Table 232. Australia Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 233. Australia Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 234. Australia Methotrexate Sales, by End User K Units (2018-2023)
  • Table 235. Rest of Asia-Pacific Methotrexate Sales, by Type K Units (2018-2023)
  • Table 236. Rest of Asia-Pacific Methotrexate Sales, by Application K Units (2018-2023)
  • Table 237. Rest of Asia-Pacific Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 238. Rest of Asia-Pacific Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 239. Rest of Asia-Pacific Methotrexate Sales, by End User K Units (2018-2023)
  • Table 240. Europe Methotrexate Sales, by Country K Units (2018-2023)
  • Table 241. Europe Methotrexate Sales, by Type K Units (2018-2023)
  • Table 242. Europe Methotrexate Sales, by Application K Units (2018-2023)
  • Table 243. Europe Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 244. Europe Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 245. Europe Methotrexate Sales, by End User K Units (2018-2023)
  • Table 246. Germany Methotrexate Sales, by Type K Units (2018-2023)
  • Table 247. Germany Methotrexate Sales, by Application K Units (2018-2023)
  • Table 248. Germany Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 249. Germany Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 250. Germany Methotrexate Sales, by End User K Units (2018-2023)
  • Table 251. France Methotrexate Sales, by Type K Units (2018-2023)
  • Table 252. France Methotrexate Sales, by Application K Units (2018-2023)
  • Table 253. France Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 254. France Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 255. France Methotrexate Sales, by End User K Units (2018-2023)
  • Table 256. Italy Methotrexate Sales, by Type K Units (2018-2023)
  • Table 257. Italy Methotrexate Sales, by Application K Units (2018-2023)
  • Table 258. Italy Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 259. Italy Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 260. Italy Methotrexate Sales, by End User K Units (2018-2023)
  • Table 261. United Kingdom Methotrexate Sales, by Type K Units (2018-2023)
  • Table 262. United Kingdom Methotrexate Sales, by Application K Units (2018-2023)
  • Table 263. United Kingdom Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 264. United Kingdom Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 265. United Kingdom Methotrexate Sales, by End User K Units (2018-2023)
  • Table 266. Netherlands Methotrexate Sales, by Type K Units (2018-2023)
  • Table 267. Netherlands Methotrexate Sales, by Application K Units (2018-2023)
  • Table 268. Netherlands Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 269. Netherlands Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 270. Netherlands Methotrexate Sales, by End User K Units (2018-2023)
  • Table 271. Rest of Europe Methotrexate Sales, by Type K Units (2018-2023)
  • Table 272. Rest of Europe Methotrexate Sales, by Application K Units (2018-2023)
  • Table 273. Rest of Europe Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 274. Rest of Europe Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 275. Rest of Europe Methotrexate Sales, by End User K Units (2018-2023)
  • Table 276. MEA Methotrexate Sales, by Country K Units (2018-2023)
  • Table 277. MEA Methotrexate Sales, by Type K Units (2018-2023)
  • Table 278. MEA Methotrexate Sales, by Application K Units (2018-2023)
  • Table 279. MEA Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 280. MEA Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 281. MEA Methotrexate Sales, by End User K Units (2018-2023)
  • Table 282. Middle East Methotrexate Sales, by Type K Units (2018-2023)
  • Table 283. Middle East Methotrexate Sales, by Application K Units (2018-2023)
  • Table 284. Middle East Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 285. Middle East Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 286. Middle East Methotrexate Sales, by End User K Units (2018-2023)
  • Table 287. Africa Methotrexate Sales, by Type K Units (2018-2023)
  • Table 288. Africa Methotrexate Sales, by Application K Units (2018-2023)
  • Table 289. Africa Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 290. Africa Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 291. Africa Methotrexate Sales, by End User K Units (2018-2023)
  • Table 292. North America Methotrexate Sales, by Country K Units (2018-2023)
  • Table 293. North America Methotrexate Sales, by Type K Units (2018-2023)
  • Table 294. North America Methotrexate Sales, by Application K Units (2018-2023)
  • Table 295. North America Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 296. North America Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 297. North America Methotrexate Sales, by End User K Units (2018-2023)
  • Table 298. United States Methotrexate Sales, by Type K Units (2018-2023)
  • Table 299. United States Methotrexate Sales, by Application K Units (2018-2023)
  • Table 300. United States Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 301. United States Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 302. United States Methotrexate Sales, by End User K Units (2018-2023)
  • Table 303. Canada Methotrexate Sales, by Type K Units (2018-2023)
  • Table 304. Canada Methotrexate Sales, by Application K Units (2018-2023)
  • Table 305. Canada Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 306. Canada Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 307. Canada Methotrexate Sales, by End User K Units (2018-2023)
  • Table 308. Mexico Methotrexate Sales, by Type K Units (2018-2023)
  • Table 309. Mexico Methotrexate Sales, by Application K Units (2018-2023)
  • Table 310. Mexico Methotrexate Sales, by Sales Channel K Units (2018-2023)
  • Table 311. Mexico Methotrexate Sales, by Dosage K Units (2018-2023)
  • Table 312. Mexico Methotrexate Sales, by End User K Units (2018-2023)
  • Table 313. Methotrexate: by Type(USD/Units)
  • Table 314. Company Basic Information, Sales Area and Its Competitors
  • Table 315. Company Basic Information, Sales Area and Its Competitors
  • Table 316. Company Basic Information, Sales Area and Its Competitors
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Methotrexate: by Type(USD Million)
  • Table 325. Methotrexate Tablet , by Region USD Million (2025-2030)
  • Table 326. Methotrexate Injection , by Region USD Million (2025-2030)
  • Table 327. Methotrexate: by Application(USD Million)
  • Table 328. Methotrexate Cancer , by Region USD Million (2025-2030)
  • Table 329. Methotrexate Arthritis , by Region USD Million (2025-2030)
  • Table 330. Methotrexate Auto-Immune Diseases , by Region USD Million (2025-2030)
  • Table 331. Methotrexate Others , by Region USD Million (2025-2030)
  • Table 332. Methotrexate: by Sales Channel(USD Million)
  • Table 333. Methotrexate Pharmacy Stores , by Region USD Million (2025-2030)
  • Table 334. Methotrexate Online Pharmacies , by Region USD Million (2025-2030)
  • Table 335. Methotrexate: by Dosage(USD Million)
  • Table 336. Methotrexate 5 mg , by Region USD Million (2025-2030)
  • Table 337. Methotrexate 7.5 mg , by Region USD Million (2025-2030)
  • Table 338. Methotrexate 10 mg , by Region USD Million (2025-2030)
  • Table 339. Methotrexate 15 mg , by Region USD Million (2025-2030)
  • Table 340. Methotrexate Others , by Region USD Million (2025-2030)
  • Table 341. Methotrexate: by End User(USD Million)
  • Table 342. Methotrexate Hospitals , by Region USD Million (2025-2030)
  • Table 343. Methotrexate Specialty Clinics , by Region USD Million (2025-2030)
  • Table 344. Methotrexate Others , by Region USD Million (2025-2030)
  • Table 345. South America Methotrexate, by Country USD Million (2025-2030)
  • Table 346. South America Methotrexate, by Type USD Million (2025-2030)
  • Table 347. South America Methotrexate, by Application USD Million (2025-2030)
  • Table 348. South America Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 349. South America Methotrexate, by Dosage USD Million (2025-2030)
  • Table 350. South America Methotrexate, by End User USD Million (2025-2030)
  • Table 351. Brazil Methotrexate, by Type USD Million (2025-2030)
  • Table 352. Brazil Methotrexate, by Application USD Million (2025-2030)
  • Table 353. Brazil Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 354. Brazil Methotrexate, by Dosage USD Million (2025-2030)
  • Table 355. Brazil Methotrexate, by End User USD Million (2025-2030)
  • Table 356. Argentina Methotrexate, by Type USD Million (2025-2030)
  • Table 357. Argentina Methotrexate, by Application USD Million (2025-2030)
  • Table 358. Argentina Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 359. Argentina Methotrexate, by Dosage USD Million (2025-2030)
  • Table 360. Argentina Methotrexate, by End User USD Million (2025-2030)
  • Table 361. Rest of South America Methotrexate, by Type USD Million (2025-2030)
  • Table 362. Rest of South America Methotrexate, by Application USD Million (2025-2030)
  • Table 363. Rest of South America Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 364. Rest of South America Methotrexate, by Dosage USD Million (2025-2030)
  • Table 365. Rest of South America Methotrexate, by End User USD Million (2025-2030)
  • Table 366. Asia Pacific Methotrexate, by Country USD Million (2025-2030)
  • Table 367. Asia Pacific Methotrexate, by Type USD Million (2025-2030)
  • Table 368. Asia Pacific Methotrexate, by Application USD Million (2025-2030)
  • Table 369. Asia Pacific Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 370. Asia Pacific Methotrexate, by Dosage USD Million (2025-2030)
  • Table 371. Asia Pacific Methotrexate, by End User USD Million (2025-2030)
  • Table 372. China Methotrexate, by Type USD Million (2025-2030)
  • Table 373. China Methotrexate, by Application USD Million (2025-2030)
  • Table 374. China Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 375. China Methotrexate, by Dosage USD Million (2025-2030)
  • Table 376. China Methotrexate, by End User USD Million (2025-2030)
  • Table 377. Japan Methotrexate, by Type USD Million (2025-2030)
  • Table 378. Japan Methotrexate, by Application USD Million (2025-2030)
  • Table 379. Japan Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 380. Japan Methotrexate, by Dosage USD Million (2025-2030)
  • Table 381. Japan Methotrexate, by End User USD Million (2025-2030)
  • Table 382. India Methotrexate, by Type USD Million (2025-2030)
  • Table 383. India Methotrexate, by Application USD Million (2025-2030)
  • Table 384. India Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 385. India Methotrexate, by Dosage USD Million (2025-2030)
  • Table 386. India Methotrexate, by End User USD Million (2025-2030)
  • Table 387. South Korea Methotrexate, by Type USD Million (2025-2030)
  • Table 388. South Korea Methotrexate, by Application USD Million (2025-2030)
  • Table 389. South Korea Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 390. South Korea Methotrexate, by Dosage USD Million (2025-2030)
  • Table 391. South Korea Methotrexate, by End User USD Million (2025-2030)
  • Table 392. Taiwan Methotrexate, by Type USD Million (2025-2030)
  • Table 393. Taiwan Methotrexate, by Application USD Million (2025-2030)
  • Table 394. Taiwan Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 395. Taiwan Methotrexate, by Dosage USD Million (2025-2030)
  • Table 396. Taiwan Methotrexate, by End User USD Million (2025-2030)
  • Table 397. Australia Methotrexate, by Type USD Million (2025-2030)
  • Table 398. Australia Methotrexate, by Application USD Million (2025-2030)
  • Table 399. Australia Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 400. Australia Methotrexate, by Dosage USD Million (2025-2030)
  • Table 401. Australia Methotrexate, by End User USD Million (2025-2030)
  • Table 402. Rest of Asia-Pacific Methotrexate, by Type USD Million (2025-2030)
  • Table 403. Rest of Asia-Pacific Methotrexate, by Application USD Million (2025-2030)
  • Table 404. Rest of Asia-Pacific Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 405. Rest of Asia-Pacific Methotrexate, by Dosage USD Million (2025-2030)
  • Table 406. Rest of Asia-Pacific Methotrexate, by End User USD Million (2025-2030)
  • Table 407. Europe Methotrexate, by Country USD Million (2025-2030)
  • Table 408. Europe Methotrexate, by Type USD Million (2025-2030)
  • Table 409. Europe Methotrexate, by Application USD Million (2025-2030)
  • Table 410. Europe Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 411. Europe Methotrexate, by Dosage USD Million (2025-2030)
  • Table 412. Europe Methotrexate, by End User USD Million (2025-2030)
  • Table 413. Germany Methotrexate, by Type USD Million (2025-2030)
  • Table 414. Germany Methotrexate, by Application USD Million (2025-2030)
  • Table 415. Germany Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 416. Germany Methotrexate, by Dosage USD Million (2025-2030)
  • Table 417. Germany Methotrexate, by End User USD Million (2025-2030)
  • Table 418. France Methotrexate, by Type USD Million (2025-2030)
  • Table 419. France Methotrexate, by Application USD Million (2025-2030)
  • Table 420. France Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 421. France Methotrexate, by Dosage USD Million (2025-2030)
  • Table 422. France Methotrexate, by End User USD Million (2025-2030)
  • Table 423. Italy Methotrexate, by Type USD Million (2025-2030)
  • Table 424. Italy Methotrexate, by Application USD Million (2025-2030)
  • Table 425. Italy Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 426. Italy Methotrexate, by Dosage USD Million (2025-2030)
  • Table 427. Italy Methotrexate, by End User USD Million (2025-2030)
  • Table 428. United Kingdom Methotrexate, by Type USD Million (2025-2030)
  • Table 429. United Kingdom Methotrexate, by Application USD Million (2025-2030)
  • Table 430. United Kingdom Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 431. United Kingdom Methotrexate, by Dosage USD Million (2025-2030)
  • Table 432. United Kingdom Methotrexate, by End User USD Million (2025-2030)
  • Table 433. Netherlands Methotrexate, by Type USD Million (2025-2030)
  • Table 434. Netherlands Methotrexate, by Application USD Million (2025-2030)
  • Table 435. Netherlands Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 436. Netherlands Methotrexate, by Dosage USD Million (2025-2030)
  • Table 437. Netherlands Methotrexate, by End User USD Million (2025-2030)
  • Table 438. Rest of Europe Methotrexate, by Type USD Million (2025-2030)
  • Table 439. Rest of Europe Methotrexate, by Application USD Million (2025-2030)
  • Table 440. Rest of Europe Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 441. Rest of Europe Methotrexate, by Dosage USD Million (2025-2030)
  • Table 442. Rest of Europe Methotrexate, by End User USD Million (2025-2030)
  • Table 443. MEA Methotrexate, by Country USD Million (2025-2030)
  • Table 444. MEA Methotrexate, by Type USD Million (2025-2030)
  • Table 445. MEA Methotrexate, by Application USD Million (2025-2030)
  • Table 446. MEA Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 447. MEA Methotrexate, by Dosage USD Million (2025-2030)
  • Table 448. MEA Methotrexate, by End User USD Million (2025-2030)
  • Table 449. Middle East Methotrexate, by Type USD Million (2025-2030)
  • Table 450. Middle East Methotrexate, by Application USD Million (2025-2030)
  • Table 451. Middle East Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 452. Middle East Methotrexate, by Dosage USD Million (2025-2030)
  • Table 453. Middle East Methotrexate, by End User USD Million (2025-2030)
  • Table 454. Africa Methotrexate, by Type USD Million (2025-2030)
  • Table 455. Africa Methotrexate, by Application USD Million (2025-2030)
  • Table 456. Africa Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 457. Africa Methotrexate, by Dosage USD Million (2025-2030)
  • Table 458. Africa Methotrexate, by End User USD Million (2025-2030)
  • Table 459. North America Methotrexate, by Country USD Million (2025-2030)
  • Table 460. North America Methotrexate, by Type USD Million (2025-2030)
  • Table 461. North America Methotrexate, by Application USD Million (2025-2030)
  • Table 462. North America Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 463. North America Methotrexate, by Dosage USD Million (2025-2030)
  • Table 464. North America Methotrexate, by End User USD Million (2025-2030)
  • Table 465. United States Methotrexate, by Type USD Million (2025-2030)
  • Table 466. United States Methotrexate, by Application USD Million (2025-2030)
  • Table 467. United States Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 468. United States Methotrexate, by Dosage USD Million (2025-2030)
  • Table 469. United States Methotrexate, by End User USD Million (2025-2030)
  • Table 470. Canada Methotrexate, by Type USD Million (2025-2030)
  • Table 471. Canada Methotrexate, by Application USD Million (2025-2030)
  • Table 472. Canada Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 473. Canada Methotrexate, by Dosage USD Million (2025-2030)
  • Table 474. Canada Methotrexate, by End User USD Million (2025-2030)
  • Table 475. Mexico Methotrexate, by Type USD Million (2025-2030)
  • Table 476. Mexico Methotrexate, by Application USD Million (2025-2030)
  • Table 477. Mexico Methotrexate, by Sales Channel USD Million (2025-2030)
  • Table 478. Mexico Methotrexate, by Dosage USD Million (2025-2030)
  • Table 479. Mexico Methotrexate, by End User USD Million (2025-2030)
  • Table 480. Methotrexate Sales: by Type(K Units)
  • Table 481. Methotrexate Sales Tablet , by Region K Units (2025-2030)
  • Table 482. Methotrexate Sales Injection , by Region K Units (2025-2030)
  • Table 483. Methotrexate Sales: by Application(K Units)
  • Table 484. Methotrexate Sales Cancer , by Region K Units (2025-2030)
  • Table 485. Methotrexate Sales Arthritis , by Region K Units (2025-2030)
  • Table 486. Methotrexate Sales Auto-Immune Diseases , by Region K Units (2025-2030)
  • Table 487. Methotrexate Sales Others , by Region K Units (2025-2030)
  • Table 488. Methotrexate Sales: by Sales Channel(K Units)
  • Table 489. Methotrexate Sales Pharmacy Stores , by Region K Units (2025-2030)
  • Table 490. Methotrexate Sales Online Pharmacies , by Region K Units (2025-2030)
  • Table 491. Methotrexate Sales: by Dosage(K Units)
  • Table 492. Methotrexate Sales 5 mg , by Region K Units (2025-2030)
  • Table 493. Methotrexate Sales 7.5 mg , by Region K Units (2025-2030)
  • Table 494. Methotrexate Sales 10 mg , by Region K Units (2025-2030)
  • Table 495. Methotrexate Sales 15 mg , by Region K Units (2025-2030)
  • Table 496. Methotrexate Sales Others , by Region K Units (2025-2030)
  • Table 497. Methotrexate Sales: by End User(K Units)
  • Table 498. Methotrexate Sales Hospitals , by Region K Units (2025-2030)
  • Table 499. Methotrexate Sales Specialty Clinics , by Region K Units (2025-2030)
  • Table 500. Methotrexate Sales Others , by Region K Units (2025-2030)
  • Table 501. South America Methotrexate Sales, by Country K Units (2025-2030)
  • Table 502. South America Methotrexate Sales, by Type K Units (2025-2030)
  • Table 503. South America Methotrexate Sales, by Application K Units (2025-2030)
  • Table 504. South America Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 505. South America Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 506. South America Methotrexate Sales, by End User K Units (2025-2030)
  • Table 507. Brazil Methotrexate Sales, by Type K Units (2025-2030)
  • Table 508. Brazil Methotrexate Sales, by Application K Units (2025-2030)
  • Table 509. Brazil Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 510. Brazil Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 511. Brazil Methotrexate Sales, by End User K Units (2025-2030)
  • Table 512. Argentina Methotrexate Sales, by Type K Units (2025-2030)
  • Table 513. Argentina Methotrexate Sales, by Application K Units (2025-2030)
  • Table 514. Argentina Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 515. Argentina Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 516. Argentina Methotrexate Sales, by End User K Units (2025-2030)
  • Table 517. Rest of South America Methotrexate Sales, by Type K Units (2025-2030)
  • Table 518. Rest of South America Methotrexate Sales, by Application K Units (2025-2030)
  • Table 519. Rest of South America Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 520. Rest of South America Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 521. Rest of South America Methotrexate Sales, by End User K Units (2025-2030)
  • Table 522. Asia Pacific Methotrexate Sales, by Country K Units (2025-2030)
  • Table 523. Asia Pacific Methotrexate Sales, by Type K Units (2025-2030)
  • Table 524. Asia Pacific Methotrexate Sales, by Application K Units (2025-2030)
  • Table 525. Asia Pacific Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 526. Asia Pacific Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 527. Asia Pacific Methotrexate Sales, by End User K Units (2025-2030)
  • Table 528. China Methotrexate Sales, by Type K Units (2025-2030)
  • Table 529. China Methotrexate Sales, by Application K Units (2025-2030)
  • Table 530. China Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 531. China Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 532. China Methotrexate Sales, by End User K Units (2025-2030)
  • Table 533. Japan Methotrexate Sales, by Type K Units (2025-2030)
  • Table 534. Japan Methotrexate Sales, by Application K Units (2025-2030)
  • Table 535. Japan Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 536. Japan Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 537. Japan Methotrexate Sales, by End User K Units (2025-2030)
  • Table 538. India Methotrexate Sales, by Type K Units (2025-2030)
  • Table 539. India Methotrexate Sales, by Application K Units (2025-2030)
  • Table 540. India Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 541. India Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 542. India Methotrexate Sales, by End User K Units (2025-2030)
  • Table 543. South Korea Methotrexate Sales, by Type K Units (2025-2030)
  • Table 544. South Korea Methotrexate Sales, by Application K Units (2025-2030)
  • Table 545. South Korea Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 546. South Korea Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 547. South Korea Methotrexate Sales, by End User K Units (2025-2030)
  • Table 548. Taiwan Methotrexate Sales, by Type K Units (2025-2030)
  • Table 549. Taiwan Methotrexate Sales, by Application K Units (2025-2030)
  • Table 550. Taiwan Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 551. Taiwan Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 552. Taiwan Methotrexate Sales, by End User K Units (2025-2030)
  • Table 553. Australia Methotrexate Sales, by Type K Units (2025-2030)
  • Table 554. Australia Methotrexate Sales, by Application K Units (2025-2030)
  • Table 555. Australia Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 556. Australia Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 557. Australia Methotrexate Sales, by End User K Units (2025-2030)
  • Table 558. Rest of Asia-Pacific Methotrexate Sales, by Type K Units (2025-2030)
  • Table 559. Rest of Asia-Pacific Methotrexate Sales, by Application K Units (2025-2030)
  • Table 560. Rest of Asia-Pacific Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 561. Rest of Asia-Pacific Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 562. Rest of Asia-Pacific Methotrexate Sales, by End User K Units (2025-2030)
  • Table 563. Europe Methotrexate Sales, by Country K Units (2025-2030)
  • Table 564. Europe Methotrexate Sales, by Type K Units (2025-2030)
  • Table 565. Europe Methotrexate Sales, by Application K Units (2025-2030)
  • Table 566. Europe Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 567. Europe Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 568. Europe Methotrexate Sales, by End User K Units (2025-2030)
  • Table 569. Germany Methotrexate Sales, by Type K Units (2025-2030)
  • Table 570. Germany Methotrexate Sales, by Application K Units (2025-2030)
  • Table 571. Germany Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 572. Germany Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 573. Germany Methotrexate Sales, by End User K Units (2025-2030)
  • Table 574. France Methotrexate Sales, by Type K Units (2025-2030)
  • Table 575. France Methotrexate Sales, by Application K Units (2025-2030)
  • Table 576. France Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 577. France Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 578. France Methotrexate Sales, by End User K Units (2025-2030)
  • Table 579. Italy Methotrexate Sales, by Type K Units (2025-2030)
  • Table 580. Italy Methotrexate Sales, by Application K Units (2025-2030)
  • Table 581. Italy Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 582. Italy Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 583. Italy Methotrexate Sales, by End User K Units (2025-2030)
  • Table 584. United Kingdom Methotrexate Sales, by Type K Units (2025-2030)
  • Table 585. United Kingdom Methotrexate Sales, by Application K Units (2025-2030)
  • Table 586. United Kingdom Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 587. United Kingdom Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 588. United Kingdom Methotrexate Sales, by End User K Units (2025-2030)
  • Table 589. Netherlands Methotrexate Sales, by Type K Units (2025-2030)
  • Table 590. Netherlands Methotrexate Sales, by Application K Units (2025-2030)
  • Table 591. Netherlands Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 592. Netherlands Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 593. Netherlands Methotrexate Sales, by End User K Units (2025-2030)
  • Table 594. Rest of Europe Methotrexate Sales, by Type K Units (2025-2030)
  • Table 595. Rest of Europe Methotrexate Sales, by Application K Units (2025-2030)
  • Table 596. Rest of Europe Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 597. Rest of Europe Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 598. Rest of Europe Methotrexate Sales, by End User K Units (2025-2030)
  • Table 599. MEA Methotrexate Sales, by Country K Units (2025-2030)
  • Table 600. MEA Methotrexate Sales, by Type K Units (2025-2030)
  • Table 601. MEA Methotrexate Sales, by Application K Units (2025-2030)
  • Table 602. MEA Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 603. MEA Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 604. MEA Methotrexate Sales, by End User K Units (2025-2030)
  • Table 605. Middle East Methotrexate Sales, by Type K Units (2025-2030)
  • Table 606. Middle East Methotrexate Sales, by Application K Units (2025-2030)
  • Table 607. Middle East Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 608. Middle East Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 609. Middle East Methotrexate Sales, by End User K Units (2025-2030)
  • Table 610. Africa Methotrexate Sales, by Type K Units (2025-2030)
  • Table 611. Africa Methotrexate Sales, by Application K Units (2025-2030)
  • Table 612. Africa Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 613. Africa Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 614. Africa Methotrexate Sales, by End User K Units (2025-2030)
  • Table 615. North America Methotrexate Sales, by Country K Units (2025-2030)
  • Table 616. North America Methotrexate Sales, by Type K Units (2025-2030)
  • Table 617. North America Methotrexate Sales, by Application K Units (2025-2030)
  • Table 618. North America Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 619. North America Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 620. North America Methotrexate Sales, by End User K Units (2025-2030)
  • Table 621. United States Methotrexate Sales, by Type K Units (2025-2030)
  • Table 622. United States Methotrexate Sales, by Application K Units (2025-2030)
  • Table 623. United States Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 624. United States Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 625. United States Methotrexate Sales, by End User K Units (2025-2030)
  • Table 626. Canada Methotrexate Sales, by Type K Units (2025-2030)
  • Table 627. Canada Methotrexate Sales, by Application K Units (2025-2030)
  • Table 628. Canada Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 629. Canada Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 630. Canada Methotrexate Sales, by End User K Units (2025-2030)
  • Table 631. Mexico Methotrexate Sales, by Type K Units (2025-2030)
  • Table 632. Mexico Methotrexate Sales, by Application K Units (2025-2030)
  • Table 633. Mexico Methotrexate Sales, by Sales Channel K Units (2025-2030)
  • Table 634. Mexico Methotrexate Sales, by Dosage K Units (2025-2030)
  • Table 635. Mexico Methotrexate Sales, by End User K Units (2025-2030)
  • Table 636. Methotrexate: by Type(USD/Units)
  • Table 637. Research Programs/Design for This Report
  • Table 638. Key Data Information from Secondary Sources
  • Table 639. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Methotrexate: by Type USD Million (2018-2023)
  • Figure 5. Global Methotrexate: by Application USD Million (2018-2023)
  • Figure 6. Global Methotrexate: by Sales Channel USD Million (2018-2023)
  • Figure 7. Global Methotrexate: by Dosage USD Million (2018-2023)
  • Figure 8. Global Methotrexate: by End User USD Million (2018-2023)
  • Figure 9. South America Methotrexate Share (%), by Country
  • Figure 10. Asia Pacific Methotrexate Share (%), by Country
  • Figure 11. Europe Methotrexate Share (%), by Country
  • Figure 12. MEA Methotrexate Share (%), by Country
  • Figure 13. North America Methotrexate Share (%), by Country
  • Figure 14. Global Methotrexate: by Type K Units (2018-2023)
  • Figure 15. Global Methotrexate: by Application K Units (2018-2023)
  • Figure 16. Global Methotrexate: by Sales Channel K Units (2018-2023)
  • Figure 17. Global Methotrexate: by Dosage K Units (2018-2023)
  • Figure 18. Global Methotrexate: by End User K Units (2018-2023)
  • Figure 19. South America Methotrexate Share (%), by Country
  • Figure 20. Asia Pacific Methotrexate Share (%), by Country
  • Figure 21. Europe Methotrexate Share (%), by Country
  • Figure 22. MEA Methotrexate Share (%), by Country
  • Figure 23. North America Methotrexate Share (%), by Country
  • Figure 24. Global Methotrexate: by Type USD/Units (2018-2023)
  • Figure 25. Global Methotrexate share by Players 2023 (%)
  • Figure 26. Global Methotrexate share by Players (Top 3) 2023(%)
  • Figure 27. Global Methotrexate share by Players (Top 5) 2023(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 31. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 33. Cumberland Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Cumberland Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Cadila Healthcare (India) Revenue, Net Income and Gross profit
  • Figure 36. Cadila Healthcare (India) Revenue: by Geography 2023
  • Figure 37. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 38. Cipla Limited (India) Revenue: by Geography 2023
  • Figure 39. Rosemont Pharmaceuticals Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. Rosemont Pharmaceuticals Limited (United Kingdom) Revenue: by Geography 2023
  • Figure 41. Antares Pharma Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Antares Pharma Inc. (United States) Revenue: by Geography 2023
  • Figure 43. Medac Pharma Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Medac Pharma Inc. (United States) Revenue: by Geography 2023
  • Figure 45. Accord Healthcare Limited (United States) Revenue, Net Income and Gross profit
  • Figure 46. Accord Healthcare Limited (United States) Revenue: by Geography 2023
  • Figure 47. Sun Pharma Laboratories Ltd (India) Revenue, Net Income and Gross profit
  • Figure 48. Sun Pharma Laboratories Ltd (India) Revenue: by Geography 2023
  • Figure 49. Global Methotrexate: by Type USD Million (2025-2030)
  • Figure 50. Global Methotrexate: by Application USD Million (2025-2030)
  • Figure 51. Global Methotrexate: by Sales Channel USD Million (2025-2030)
  • Figure 52. Global Methotrexate: by Dosage USD Million (2025-2030)
  • Figure 53. Global Methotrexate: by End User USD Million (2025-2030)
  • Figure 54. South America Methotrexate Share (%), by Country
  • Figure 55. Asia Pacific Methotrexate Share (%), by Country
  • Figure 56. Europe Methotrexate Share (%), by Country
  • Figure 57. MEA Methotrexate Share (%), by Country
  • Figure 58. North America Methotrexate Share (%), by Country
  • Figure 59. Global Methotrexate: by Type K Units (2025-2030)
  • Figure 60. Global Methotrexate: by Application K Units (2025-2030)
  • Figure 61. Global Methotrexate: by Sales Channel K Units (2025-2030)
  • Figure 62. Global Methotrexate: by Dosage K Units (2025-2030)
  • Figure 63. Global Methotrexate: by End User K Units (2025-2030)
  • Figure 64. South America Methotrexate Share (%), by Country
  • Figure 65. Asia Pacific Methotrexate Share (%), by Country
  • Figure 66. Europe Methotrexate Share (%), by Country
  • Figure 67. MEA Methotrexate Share (%), by Country
  • Figure 68. North America Methotrexate Share (%), by Country
  • Figure 69. Global Methotrexate: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • GlaxoSmithKline (United Kingdom)
  • Cumberland Pharmaceuticals Inc. (United States)
  • Cadila Healthcare (India)
  • Cipla Limited (India)
  • Rosemont Pharmaceuticals Limited (United Kingdom)
  • Antares Pharma Inc. (United States)
  • Medac Pharma Inc. (United States)
  • Accord Healthcare Limited (United States)
  • Sun Pharma Laboratories Ltd (India)
Additional players considered in the study are as follows:
Alkem Laboratories Ltd. (India) , Ranbaxy Laboratories Ltd. (India) , Ipca Laboratories Private Ltd. (India) , Mylan (United States) , Sandoz (Novartis), Germany , Hikma Pharmaceuticals (United Kingdom) , Teva Pharmaceutical Industries (Israel) , ROVI Pharmaceutical Company , Pharmacia (United States) , Remedica Ltd (Cyprus) , Kalbe Farma (Indonesia)
Select User Access Type

Key Highlights of Report


Apr 2024 156 Pages 82 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Methotrexate Market Quantitative research analysis
Global Methotrexate Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Methotrexate study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Methotrexate Market is gaining popularity and expected to see strong valuation by 2030 .
According to AMA, the Global Methotrexate market is expected to see growth rate of xx%.
The Methotrexate market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Methotrexate Market Report?

Have a Query? Click Here

Other Related Reports

Effervescent Products Comprehensive Study by Type (Prescription-Based, Daily-Use), Application (Pharmaceuticals, Functional Foods (Probiotics, Dietary Supplements, Electrolytes & Energy Boosting Supp...
$ 3750
Ibrutinib Comprehensive Study by Application (Chronic Lymphocytic Leukaemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL), Multiple Myeloma (MM), Follicular Lymphoma (FL), ...
$ 3650
Paclitaxel Comprehensive Study by Type (Natural Paclitaxel, Semi-synthetic Paclitaxel), Application (Breast Cancer, Ovarian Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer, Stomach Cancer, Othe...
$ 3450
Cough Remedies Comprehensive Study by Type (Antihistamines, Expectorants, Bronchodilators, Decongestants, Antibiotics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stor...
$ 3650
Homeopathy Products Comprehensive Study by Type (Tincture, Dilutions, Ointments, Tablets, Others), Application (Analgesic & Antipyretic, Respiratory, Neurology, Immunology, Gastroenterology, Dermatol...
$ 3350
Vitamins Comprehensive Study by Type (Fat-soluble, Water-soluble), Application (Food & Beverages, Personal Care, Animal Feed, Pharmaceuticals), Distribution Channel (Hypermarket, Supermarket, Mass m...
$ 3450